February 3, 2021 05:15 PM ESTUpdated February 4, 10:47 AM
FDA+

Prothena re­vives its for­mer lead drug, aim­ing for a small­er pop­u­la­tion with more se­vere cas­es

Max Gelman

Senior Editor

A high-pro­file AL amy­loi­do­sis pro­gram once left for dead has got­ten new life.

Prothena is push­ing for­ward with its for­mer lead can­di­date NEOD001, now called …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times